Literature DB >> 22899510

Application of high-resolution ESI and MALDI mass spectrometry to metabolite profiling of small interfering RNA duplex.

Hisao Shimizu1, Fumihiro Jinno, Akio Morohashi, Yuzo Yamazaki, Masaki Yamada, Takahiro Kondo, Satoru Asahi.   

Abstract

We investigated the application of a high-resolution Orbitrap mass spectrometer equipped with an electrospray ionization (ESI) source and a matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometer to the metabolite profiling of a model small interfering RNA (siRNA) duplex TSR#34 and compared their functions and capabilities. TSR#34 duplex was incubated in human serum in vitro, and the duplex and its metabolites were then purified by ion exchange chromatography in order to remove the biological matrices. The fraction containing the siRNA duplex and its metabolites was collected and desalted and then subjected to high-performance liquid chromatography (HPLC) equipped with a reversed phase column. The siRNA and its metabolites were separated into single strands by elevated chromatographic temperature and analyzed using the ESI-Orbitrap or the MALDI-TOF mass spectrometer. Using this method, the 5' and/or 3' truncated metabolites of each strand were detected in the human serum samples. The ESI-Orbitrap mass spectrometer enabled differentiation between two possible RNA-based sequences, a monoisotopic molecular mass difference which was less than 2 Da, with an intrinsic mass resolving power. In-source decay (ISD) analysis using a MALDI-TOF mass spectrometer allowed the sequencing of the RNA metabolite with characteristic fragment ions, using 2,4-dihydroxyacetophenone (2,4-DHAP) as a matrix. The ESI-Orbitrap mass spectrometer provided the highest mass accuracy and the benefit of on-line coupling with HPLC for metabolite profiling. Meanwhile, the MALDI-TOF mass spectrometer, in combination with 2,4-DHAP, has the potential for the sequencing of RNA by ISD analysis. The combined use of these methods will be beneficial to characterize the metabolites of therapeutic siRNA compounds.
Copyright © 2012 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22899510     DOI: 10.1002/jms.3054

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  4 in total

1.  High-Yield Synthesis of Monomeric LMWP(CPP)-siRNA Covalent Conjugate for Effective Cytosolic Delivery of siRNA.

Authors:  Junxiao Ye; Ergang Liu; Junbo Gong; Jianxin Wang; Yongzhuo Huang; Huining He; Victor C Yang
Journal:  Theranostics       Date:  2017-06-25       Impact factor: 11.556

2.  Improved method for synthesis of low molecular weight protamine-siRNA conjugate.

Authors:  Zhili Yu; Junxiao Ye; Xing Pei; Lu Sun; Ergang Liu; Jianxin Wang; Yongzhuo Huang; Seung Jin Lee; Huining He
Journal:  Acta Pharm Sin B       Date:  2017-12-19       Impact factor: 11.413

Review 3.  Unveiling the druggable RNA targets and small molecule therapeutics.

Authors:  Joanna Sztuba-Solinska; Gabriela Chavez-Calvillo; Sabrina Elizabeth Cline
Journal:  Bioorg Med Chem       Date:  2019-03-30       Impact factor: 3.641

4.  19 F NMR-Based Fragment Screening for 14 Different Biologically Active RNAs and 10 DNA and Protein Counter-Screens.

Authors:  Oliver Binas; Vanessa de Jesus; Tom Landgraf; Albrecht Eduard Völklein; Jason Martins; Daniel Hymon; Jasleen Kaur Bains; Hannes Berg; Thomas Biedenbänder; Boris Fürtig; Santosh Lakshmi Gande; Anna Niesteruk; Andreas Oxenfarth; Nusrat Shahin Qureshi; Tatjana Schamber; Robbin Schnieders; Alix Tröster; Anna Wacker; Julia Wirmer-Bartoschek; Maria Alexandra Wirtz Martin; Elke Stirnal; Kamal Azzaoui; Christian Richter; Sridhar Sreeramulu; Marcel Jules José Blommers; Harald Schwalbe
Journal:  Chembiochem       Date:  2020-09-25       Impact factor: 3.461

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.